~~United States~~

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON,~~

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the ~~Quarterly Period Ended September~~quarterly period ended June 30, ~~2017~~

2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission File ~~Number~~No. 0-20791

~~AMARILLO BIOSCIENCES, INC.~~

~~(Exact name of registrant as specified in its charter)~~

~~TEXAS~~		~~75-1974352~~ AINOS, INC.
(Exact name of registrant as specified in its charter)

Texas	75-1974352
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

		8880 Rio San Diego Drive, Ste. 800, San Diego, CA 92108 (858) 869-2986
~~4134 Business Park Drive, Amarillo, Texas 79110~~
(Address ~~of principal executive offices) (Zip Code)~~


~~(806) 376-1741~~
~~(Issuer's~~and telephone number, including area ~~code)~~code, of registrant's principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	AIMD	The Nasdaq Stock Market LLC
Warrants to purchase Common Stock	AIMD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ~~[√ ]~~ ☒ Yes ~~[ ]~~ ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated ~~filer"~~filer," "smaller reporting company," and ~~"smaller reporting~~"emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ~~[ ]~~	☐	Accelerated filer ~~[ ]~~	☐
Non-accelerated ~~filer [ ] (do not check if smaller reporting company)~~Filer	☒	Smaller reporting company ~~[√]~~	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ~~[ ]~~ ☐ Yes ~~[√]~~ ☒ No

~~As of November 20, 2017, there were 23,156,563~~

19,478,270 shares of ~~the issuer's~~ common stock, ~~outstanding.~~

~~AMARILLO BIOSCIENCES, INC.~~

~~INDEX~~

par value $0.01 per share, outstanding as of August 12, 2022

		~~PAGE NO.~~
~~PART I:~~	~~FINANCIAL INFORMATION~~


~~ITEM 1.~~	~~Financial Statements~~

AINOS, INC.

INDEX

		PAGE NO.
PART I:	FINANCIAL INFORMATION	3

ITEM 1.	Financial Statements	3

	Balance Sheets– ~~September~~June 30, ~~2017~~2022 and December 31, ~~2016~~2021 (unaudited)	3

	Statements of Operations – Three and ~~Nine~~Six Months Ended ~~September~~June 30, ~~2017~~2022 and ~~2016~~2021 (unaudited)	4

	Statements of Stockholders’ Equity (Deficit) – Six Months Ended June 30, 2022 and 202 (unaudited)	6

	Condensed Statements of Cash Flows – ~~Nine~~Six Months Ended ~~September~~June 30, ~~2017~~2022 and ~~2016~~2021 (unaudited)	5 8

	Notes to Financial Statements (unaudited)	6 9

ITEM 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	10 15

ITEM 3.	Quantitative and Qualitative Disclosures About Market ~~Risk.~~Risk	15 22

ITEM 4.	Controls and Procedures	15 22

PART II:	OTHER INFORMATION
~~ITEM 1.~~	~~Legal Proceedings~~	16
ITEM 1.	Legal Proceedings	24

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	16 24

ITEM 3.	Defaults Upon Senior Securities	17 25

ITEM 4.	Mine Safety Disclosures	17 25
~~ITEM 5.~~	~~Other Information~~	17
ITEM 5.	Other Information	25

ITEM 6.	~~Exhibits……………………………………………………………~~ Exhibits	17 26

Signatures		27

Table of Contents

PART I - FINANCIAL INFORMATION

~~ITEM 1.~~

~~Financial Statements~~

~~Amarillo Biosciences,~~

ITEM 1. Financial Statements

Ainos, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

September 30,
2017

December 31,
2016

Assets
Current assets:
   Cash and cash equivalents $ 145,029 $ 134,125
   Inventory - 14,700
   Advance to related party 28,584 37,835
   Prepaid expense and other current assets 38,718 75,739
Total current assets 212,331 262,399
Patents, net 179,208 156,063
Property and equipment, net 31,302 44,214
Total assets $ 422,841 $ 462,676

Liabilities and Stockholders' Deficit
Current liabilities:
   Accounts payable and accrued expenses $ 175,339 $ 165,502
   Accrued interest - related parties 10,018 3,259
   Advance from related party 187,500 187,500
   Stock subscription deposit 142,107 -
   Customer deposits – related parties - 124,833
   Convertible note payable – related party 886,481 791,481
Total current liabilities 1,401,445 1,272,575
Total liabilities 1,401,445 1,272,575

Commitments and contingencies
Stockholders' deficit
   Preferred stock, $0.01 par value:
     Authorized shares - 10,000,000,
Issued and outstanding shares – 0 at September 30, 2017 and December 31, 2016 - -
   Common stock, $0.01 par value:
     Authorized shares - 100,000,000,
Issued and outstanding shares – 23,078,668 and 21,916,143 at September 30, 2017 and December 31, 2016, respectively 230,787 219,161
   Additional paid-in capital 465,960 237,540
   Accumulated deficit (1,675,351 ) (1,266,600 )
Total stockholders' deficit (978,604 ) (809,899 )
Total liabilities and stockholders' deficit $ 422,841 $ 462,676

	June 30,			December 31,
	2022			2021
Assets
Current assets:
Cash and cash equivalents	$	1,753,877		$	1,751,499
Inventory		670,507			0
Other current assets		1,274,512			466,198
Total current assets		3,698,896			2,217,697
Intangible assets, net		35,086,424			37,329,191
Property and equipment, net		1,503,025			1,187,702
Other assets		124,697			87,571
Total assets	$	40,413,042		$	40,822,161

Liabilities and Stockholders' Equity
Current liabilities:
Convertible notes payable	$	3,376,526		$	3,376,526
Notes payable		1,013,405			213,405
Accrued expenses and others current liabilities		2,598,468			1,004,868
Payables – related party		0			26,000,000
Total current liabilities		6,988,399			30,594,799
Long term liabilities:
Convertible notes payable - noncurrent		27,400,000			0
Operating lease liabilities - noncurrent		18,323			30,255
Total long term liabilities		27,418,323			30,255
Total liabilities		34,406,722			30,625,054

Stockholders' equity
Preferred stock, $0.01 par value; 10,000,000 shares
authorized; none issued
Common stock, $0.01 par value; 300,000,000 shares
authorized as of June 30, 2022 and December 31,
2021; 144,379,308 shares issued and outstanding as
of June 30, 2022 and December 31, 2021		1,443,793			1,443,793
Additional paid-in capital		18,943,316			18,856,430
Accumulated deficit		(14,162,843	)		(10,108,916	)
Translation adjustment		(217,946	)		5,800
Total stockholders’ equity		6,006,320			10,197,107
Total liabilities and stockholders’ equity	$	40,413,042		$	40,822,161

See accompanying notes to condensed consolidated financial statements.

~~Amarillo Biosciences,~~

Table of Contents

Ainos, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

Three months ended
September 30
       Nine months ended
September 30
2017 2016 2017 2016
Revenues:
   Sales – ACM $ - $ - $ 250,502 $ -
   Sales – Herbs - - - 4.400
      Total revenues - - 250,502 4,400

Cost of revenues:

  Product sales - - 58,801 5,100
      Total cost of revenues - - 58,801 5,100
Gross Margin - - 191,701 (700 )

Operating expenses:
  Research and development expenses - - - -
  Selling, general and administrative expenses 230,875 178,470 592,822 434,176
     Total operating expenses 230,875 178,470 592,822 434,176

Operating loss (230,875 ) (178,470 ) (401,121 ) (434,876 )

Other income (expense):
  Interest expense (1,929 ) (798 ) (7,630 ) (2,257 )
Net loss (232,804 ) $ (179,268 ) (408,751 ) $ (437,133 )

Basic and diluted net loss per share $ (0.01 ) $ (0.01 ) $ (0.02 ) $ (0.02 )

Weighted average shares outstanding – basic and diluted 22,789,370 21,394,810 22,500,663 20,871,635

	Three months ended June 30						Six months ended June 30
	2022			2021			2022			2021

Revenues	$	636,627		$	202,992		$	723,828		$	205,113
Cost of revenues		(318,963	)		(69,508	)		(360,042	)		(70,757	)
Gross profit		317,664			133,484			363,786			134,356
Operating expenses
Research and development expenses		1,634,856			0			3,212,310			0
Selling, general and administrative expenses		627,104			860,030			1,178,834			1,383,011
Total operating expenses		2,261,960			860,030			4,391,144			1,383,011

Operating loss		(1,944,296	)		(726,546	)		(4,027,358	)		(1,248,655	)

Non-operating income and expense, net
Loss on sale of fixed assets		-			(2,247	)		-			(2,247	)
Interest expense, net		(18,796	)		(20,981	)		(35,483	)		(32,879	)
Other income, net		9,060			0			8,914			0
Total non-operating income and expenses, net		(9,736	)		(23,228	)		(26,569	)		(35,126	)
Net loss		(1,954,032	)		(749,774	)		(4,053,927	)		(1,283,781	)

Basic and diluted net loss per share attributable to common shareholders	$	(0.01	)	$	(0.01	)	$	(0.03	)	$	(0.02	)

Weighted average common shares outstanding – basic and diluted		144,379,308			124,644,759			144,379,308			83,583,583

See accompanying notes to condensed consolidated financial statements.

~~Amarillo Biosciences,~~

Table of Contents

Ainos, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

	Three months ended June 30						Six months ended June 30
	2022			2021			2022			2021

Net loss	$	(1,954,032	)	$	(749,774	)	$	(4,053,927	)	$	(1,283,781	)
Other comprehensive loss:
Translation adjustment		(165,687	)		-			(223,746	)		-
Comprehensive loss	$	(2,119,719	)	$	(749,774	)	$	(4,277,673	)	$	(1,283,781	)

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Ainos, Inc.

Statements of Stockholders’ Equity (Deficit)

For the three months ended June, 2022 and 2021

(Unaudited)

	Preferred Stock				Common Stock				Additional Paid		Accumulated			Translation
	Shares		Par Value		Shares		Par Value		in Capital		Deficit			Adjustment			Total

Balance at March 31, 2022		-	$	0		144,379,308	$	1,443,793	$	18,899,873	$	(12,208,811	)	$	(52,259	)	$	(8,082,596	)
Warrant expense		-		0		-		0		3,417		0			0			3,417
Option expense		-		0		-		0		40,026		0			0			40,026
Net loss		-		0		-		0		0		(1,954,032	)		0			(1,954,032	)
Translation adjustment		-		0		-		0		0		0			(165,687	)		(165,687	)
Balance at June 30, 2022		-	$	0		144,379,308	$	1,443,793	$	18,943,316	$	(14,162,843	)		(217,946	)	$	6,006,320

Balance at March 31, 2021		-		0		42,066,172	$	420,662	$	5,055,420	$	(6,754,261	)		0		$	(1,278,179	)
Issuance of stock for compensation		-		0		205,643		2,056		137,349		0			0			139,405
Issuance of stock for acquisition of patents		-		0		100,000,000		1,000,000		19,000,000		0			0			20,000,000
Warrant expense		-		0		-		0		3,417		0			0			3,417
Option expense		-		0		-		0		90,688		0			0			90,688
Net loss		-		0		-		0		0		(749,774	)		0			(749,774	)
Balance at June 30, 2021		-	$	0		142,271,815	$	1,422,718	$	24,286,874	$	(7,504,035	)		0		$	18,205,557

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Ainos, Inc.

Statements of Stockholders’ Equity (Deficit)

For the six months ended June, 2022 and 2021

(Unaudited)

	Preferred Stock				Common Stock				Additional Paid in		Accumulated			Translation
	Shares		Par Value		Shares		Par Value		Capital		Deficit			Adjustment			Total

Balance at December 31, 2021		-	$	-		144,379,308	$	1,443,793	$	18,856,430	$	(10,108,916	)	$	5,800		$	10,197,107
Warrant expense		-		0		-		0		6,834		0			0			6,834
Option expense		-		0		-		0		80,052		0			0			80,052
Net loss		-		0		-		0		0		(4,053,927	)		0			(4,053,927	)
Translation adjustment		-		0		-		0		0		0			(223,746	)		(223,746	)
Balance at June 30, 2022		-	$	0		144,379,308	$	1,443,793	$	18,943,316	$	(14,162,843	)		(217,946	)	$	6,006,320

Balance at December 31, 2020		-		0		42,066,172	$	420,662	$	4,961,315	$	(6,220,255	)		0		$	(838,278	)
Issuance of stock for compensation		-		0		205,643		2,056		137,349		0			0			139,405
Issuance of stock for acquisition of patents		-		0		100,000,000		1,000,000		19,000,000		0			0			20,000,000
Warrant expense		-		0		-		0		6,835		0			0			6,835
Option expense		-		0		-		0		181,376		0			0			181,376
Net loss		-		0		-		0		0		(1,283,781	)		0			(1,283,781	)
Balance at June 30, 2021		-	$	0		142,271,815	$	1,422,718	$	24,286,874	$	(7,504,035	)		0		$	18,205,557

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Ainos, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

Nine months ended
September 30, 2017

Nine months ended
September 30, 2016

Net cash used in operating activities: $ (188,526 ) $ (426,988 )

Cash flows from investing activities:
   Investment in equipment - (47,685 )
   Investment in patents (39,945 ) (54,483 )
      Net cash used in investing activities (39,945 ) (102,168 )

Cash flows from financing activities:
   Proceeds from private placement offering 144,375 421,875
   Proceeds from convertible note payable – related party 95,000 262,500
     Net cash provided by financing activities 239,375 684,375

Net change in cash 10,904 155,219
Cash and cash equivalents at beginning of period 134,125 21,138
Cash and cash equivalents at end of period $ 145,029 $ 176,357
Supplemental disclosure of cash flow information
   Cash paid for interest $ - $ 1,066
   Cash paid for income taxes $ - $ -
Noncash transactions:
Common stock shares issued for services $ 10,671 $ -
Conversion of accounts payable – related party to convertible note payable – related party $ - $ 144,426
Conversion of notes payable – related party to convertible note payable – related party $ - $ 384,555

	Six months ended June 30,
	2022			2021
Cash flows from operating activities:
Net loss	$	(4,053,927	)	$	(1,283,781	)
Adjustments to reconcile net loss to net cash used in operating. activities:
Depreciation and amortization		2,378,835			514,850
Share-based compensation expense		86,886			188,210
Stock issued for compensation		-			139,405
Interest expense		36,202			32,934
Loss on disposal of fixed assets		-			2,247
Changes in operating assets and liabilities:
Accounts receivable		(29,881	)		(139,747	)
Inventory		(670,507	)		3,024
Other current assets		(775,909	)		(71,941	)
Accrued expenses and other current liabilities		802,282			238,110
Contract liabilities		606,866			333,763
Net cash used in operating activities		(1,619,153	)		(42,926	)
Cash flows from investing activities:
Acquisition of property and equipment		(424,557	)		(23,312	)
Proceeds from disposal of property and equipment					36
Net cash used in investing activities		(424,557	)		(23,276	)
Cash flows from financing activities
Proceeds from convertible notes payable		1,400,000			652,395
Proceeds from notes payable		800,000			0
Payments of lease liabilities		(10,125	)		(1,800	)
Net cash provided by financing activities		2,189,875			650,595
Net change in cash		146,165			584,393
Effect from foreign currency exchange		(143,787	)		0
Cash and cash equivalents at beginning of period		1,751,499			22,245
Cash and cash equivalents at end of period		1,753,877			606,638

Supplemental disclosures of noncash financing and investing activities
Issuance of convertible notes for payables - related party		26,000,000			0
Stock issued for acquisition of patents		-			20,000,000
Stock issued for compensation		-			139,405
Net change in equipment payable		117,185			0
ROU leased assets		-			62,846

See accompanying notes to the condensed consolidated financial statements.

~~Amarillo Biosciences,~~

Table of Contents

Ainos, Inc.

Notes to Financial Statements

(Unaudited)

Organization and Business. Ainos, Inc., a Texas corporation formerly known as Amarillo Biosciences, Inc. (the "Company", "we" or ~~"ABI"~~"us"), ~~a Texas corporation formed in 1984,~~ is engaged in developing ~~biologics~~medical technologies for ~~the~~point-of-care (“POCT”) testing and safe and novel medical treatment for a broad range of ~~human~~disease indications. Since our inception in 1984, we have concentrated our resources on business planning, raising capital, research and ~~animal diseases. The Company's current focus is research aimed at the treatment~~clinical development activities for our programs, securing related intellectual property and commercialization of ~~human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications~~proprietary therapeutics using ~~natural human~~low-dose non-injectable interferon ~~alpha that is administered in a proprietary low dose oral form.~~(“IFN”). In addition to our core IFN technology, we are committed to developing a diversified healthcare business portfolio to include medical devices and consumer healthcare products. Although we have historically been involved in extensive pharmaceutical research and development of low-dose oral interferon as a therapeutic, we are prioritizing the ~~above core technology, which is included in~~commercialization of medical devices as part of our diversification strategy. Since April 15, 2021, we have acquired significant intellectual property from our majority shareholder, Ainos, Inc., a Cayman Islands corporation (“Ainos KY”), to expand our potential product portfolio into Volatile Organic Compounds (“VOC”) POCTs and COVID-19 POCTs. We expect our underlying intellectual property to enable us to expedite the ~~Pharmaceutical Division, ABI is exploring~~commercialization of our medical device pipeline, beginning with the ~~possibility of instituting new revenue streams with a Medical Division and a Consumer Products Division.~~

Ainos-branded COVID-19 POCT product candidates.

The Medical Division opened a diabetic treatment center in Hong Kong in February 2017, and has deployed diabetic treatment centers in Taiwan. These centers will provide a proprietary therapy for the management of Type 1 and Type 2 diabetes along with the reversal of the complications that historically accompany this disease and plague patients. The Consumer Product Division is presently working on a delivery system for nutraceuticals and food supplements such as Vitamin C. The Company continues negotiations to import and distribute to the Asian markets a natural resource product which can be modified for human, animal, or agricultural applications. Additionally, ABI has entered the alternative medicine market through domestic and international distribution of natural Kentucky Wild Ginseng and other medicinal herbs.

Basis of presentation. The accompanying consolidated financial statements, which should be read in conjunction with the audited financial statements and footnotes included in the ~~Company's~~Company’s Form ~~10-K~~10-K/A for the year ended December 31, ~~2016,~~2021, as filed with the Securities and Exchange Commission (the “SEC”) on April ~~17, 2017,~~15, 2022 and the un-audited financial statements and footnotes included in the Company’s Form 10-Q for the quarter ending March 31, 2022 as filed with the SEC on May 16, 2022, have been prepared in accordance with ~~accounting principles generally accepted in~~ the ~~United States~~Generally Accepted Accounting Principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by ~~accounting principles generally accepted in the United States~~ for ~~complete~~audited financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2022, are not necessarily indicative of the results that may be expected for the full year ending December 31, ~~2017.~~

2022.

Financial Condition. These financial statements have been prepared in accordance with ~~United States generally accepted accounting principles,~~GAAP, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has ~~not yet achieved sustained operating income, and its operations are funded primarily~~generated revenues from ~~debt and equity financings.~~sales of COVID-19 antigen test kits since the second quarter of 2021. However, losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability.

The Company’s operations have been funded primarily from related-party convertible debt and equity financings. In addition, the Company received additional funding through a public offering concurrent with an uplisting to the Nasdaq Capital Markets, as described in Note 9.

financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.

There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company's liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern.

The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.

Table of Contents

There can be no assurance that capital will be available as necessary to meet the Company’s working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company’s liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors may raise uncertainty regarding our ability to continue as a going concern.

Common Stock. ~~The shareholders~~ We have ~~authorized 100,000,000~~300,000,000 shares of voting common shares authorized for issuance. ~~On September~~As of June 30, ~~2017,~~2022, a total of ~~28,731,754~~162,740,264 shares of common stock were either issued ~~(23,078,668)~~(144,379,308), or reserved for conversion of convertible debt to stock ~~(4,817,305)~~(17,358,339), ~~issuance to two Company officers as compensation, or~~ held for future ~~issue~~exercise of stock options (550,000) and shares reserved for warrant conversion (452,617). We also have $27,400,000 outstanding in convertibles notes which are convertible into shares of common stock upon and at a conversion price equal to 80% of the offering price of any public offering if the Company’s common stock is listed on a ~~prepaid private placement investment (757,904).~~national exchange.

On March 10, 2016, the Board of Directors approved the Company to enter into private placements for the sale of up to 5,000,000 shares of the Company's common stock (Private Placement 2016-2) at a price of $.1875 per share (aggregate offering amount of $937,500).

On September 30, 2016, the Board of Directors approved the Company to amend the previously authorized Private Placement 2016-2 offer, sale, and issuance of unregistered securities. The Private Placement 2016-2 was amended to offer up to 10,000,000 shares of the Company's common stock at a price of $.1875 per share for an aggregate offering amount of $1,875,000. The offering is to be completed within one (1) year of the date of approval.

During the first quarter of 2017, the Company sold 270,000 shares of common stock at $.1875 per share for proceeds of $50,625. No stock was sold during the second quarter of 2017. During third quarter of 2017, the Company sold 500,000 shares of common stock at $.1875 per share for aggregate proceeds of $93,750. One of the investors was ABI Chairman, CEO, and President Dr. Stephen T. Chen purchasing 200,000 common shares at $.1875 per share for total proceeds of $37,500.

On January 3, 2017, Stephen T. Chen, CEO, and Bernard Cohen, CFO/VP, received 145,405 shares of common stock and 19,387 shares of common stock, respectively, as payment of a 2016 stock bonus totaling $42,500. The stock was issued at a price of $.2579 per share pursuant to the Board of Directors resolution of December 20, 2016. The shares are recognized as stock compensation expense for the period ended December 31, 2016.

On April 3, 2017, Stephen T. Chen, CEO, and Bernard Cohen, CFO/VP, received 76,095 shares of common stock and 10,146 shares of common stock, respectively, as payment of a Q1 2017 stock bonus totaling $21,250. The stock was issued at a price of $.2464 per share. The shares are recognized as stock compensation expense for the quarter ended March 31, 2017.

On July 7, 2017, Stephen T. Chen, CEO, and Bernard Cohen, CFO/VP, received 74,552 shares of common stock and 9,940 shares of common stock, respectively, as payment of a Q2 2017 stock bonus totaling $21,250. The stock was issued at a price of $.2515 per share. The shares are recognized as stock compensation expense for the quarter ended June 30, 2017.

~~On August 1, 2017, 57,000 common shares were issued at of $.1875 per share representing payment of aggregate finders' fees in the amount of $10,671.~~

In September 2017, the Company entered into a subscription agreement to sell approximately $1.4M in shares at $0.1875 per share (7,579,059 shares). The Company accepted a 10% deposit of $142,107 which is recorded on the balance sheet as Stock Subscription Deposit. As of the filing date no shares have been issue.

On October 26, 2017, the Board of Directors unanimously approved a Consent Resolution authorizing the Company to amend the Private Placement 2016-2 offering to be extended through April 26, 2018 and to offer an additional 5,000,000 shares at a price of $.1875 per share. This amendment increased the aggregate offering amount to $2,812,500. On October 31, 2017, the Company filed the requisite Form D disclosing the amendment.

5.
	We have not paid any dividends to our common stock shareholders to date, and have no plans to do so in the immediate future.

5.	Preferred Stock. We have 10,000,000 shares of preferred stock authorized for issuance. No shares of preferred stock were outstanding as of June 30, 2022.

Current Convertible Notes Payable ~~– Related Party.~~ ~~During the fiscal year ended~~and Other Notes Payable. As of June 30, 2022 and December 31, ~~2016, a payable in~~2021, the amount of ~~$144,426~~current convertible and other notes payable totaled $4,389,931 and $3,589,931, respectively. The details of the convertible notes payable and other notes payable are shown in the table below:

Payee	No.	Effective Date	Due Date	From Effective	Following Maturity	Conversion Rate	Issuing Purpose	As of 12/31/2021	Addition	Payment	As of 6/30/2022		Accrued Interest
Current Convertible Notes Payable:
Stephen Chen	#1.16	1/30/2016	Payable on demand	0.75%	N/A	$ 0.17	working capital	114,026	0	0	114,026	6,263
Stephen Chen	#2.16	3/18/2016	Payable on demand	0.65%	N/A	$ 0.19	working capital	262,500	0	0	262,500	10,724
								376,526	0	0	376,526	16,987
Ainos KY	#12.21	4/27/2021	2/28/2023 (1)	1.85%	N/A	$ 0.20	working capital	15,000	0	0	15,000	326
Ainos KY	#13.21	5/5/2021	2/28/2023 (1)	1.85%	N/A	$ 0.20	working capital	20,000	0	0	20,000	427
Ainos KY	#14.21	5/25/2021	2/28/2023 (1)	1.85%	N/A	$ 0.20	working capital	30,000	0	0	30,000	610
Ainos KY	#15.21	5/28/2021	2/28/2023 (1)	1.85%	N/A	$ 0.20	working capital	35,000	0	0	35,000	706
Ainos KY	#16.21	6/9/2021	2/28/2023 (1)	1.85%	N/A	$ 0.20	working capital	300,000	0	0	300,000	5,869
Ainos KY	#17.21	6/21/2021	2/28/2023 (1)	1.85%	N/A	$ 0.20	working capital	107,000	0	0	107,000	2,028
Ainos KY	#18.21	7/2/2021	2/28/2023 (1)	1.85%	N/A	$ 0.20	working capital	54,000	0	0	54,000	994
Ainos KY	#19.21	9/1/2021	2/28/2023 (1)	1.85%	N/A	$ 0.20	working capital	120,000	0	0	120,000	1,843
Ainos KY	#20.21	9/28/2021	2/28/2023 (1)	1.85%	N/A	$ 0.20	working capital	300,000	0	0	300,000	4,182
Ainos KY	#21.21	11/10/2021	2/28/2023 (1)	1.85%	N/A	$ 0.20	working capital	50,000	0	0	50,000	588
Ainos KY	#22.21	11/25/2021	2/28/2023 (1)	1.85%	N/A	$ 0.20	working capital	450,000	0	0	450,000	4,927
Ainos KY	#23.21	11/29/2021	2/28/2023 (1)	1.85%	N/A	$ 0.20	working capital	300,000	0	0	300,000	3,224
Ainos KY	#24.21	12/29/2021	2/28/2023 (1)	1.85%	N/A	$ 0.20	working capital	1,219,000	0	0	1,219,000	11,307
								3,000,000	0	0	3,000,000	37,029
Total convertible notes payable- related parties								3,376,526	0	0	3,376,526	54,016
Non-Convertible Notes Payable:
Stephen Chen	#9.21	1/1/2021	4/14/2021	0.13%	N/A	N/A	working capital	129,405	0	0	129,405	396
Ainos KY	#26.22 (2)	3/4/2022	3/31/2023	1.85%	N/A	N/A	working capital	-	800,000	0	800,000	4,825
			Non-convertible notes payable-related party					129,405	800,000	0	929,405	5,221
i2 China	#8b.20	1/1/2020	1/1/2021	1.85%	N/A	N/A	consulting fee	84,000	0	0	84,000	3,922
			Non-Convertible Notes payable- non-related party					84,000			84,000	3,922
			Total non-convertible notes payable					213,405	800,000	-	1,013,405	9,143
		Total convertible and non-convertible						3,589,931	800,000	0	4,389,931	63,159

Table of Contents

Notes:

(1)	On March 17, 2022, we executed a Promissory Note Extension Agreement with Ainos KY in which the due dates for certain convertible notes enumerated as #12.21 to #24.21 issued by the Company to Ainos KY were extended to February 28, 2023. The total unpaid principal for these extended period convertible notes amount to $3,000,000 in the aggregate.
(2)	On March 11, 2022, the Board approved a Non-Convertible Note dated March 4, 2022 in favor of Ainos KY with a principal amount of $800,000, interest of 1.85% per annum on unpaid principal and accrued interest, and a maturity date of February 28, 2023. The Note includes standard provisions for notice, default, and remedies for default.

	All of the aforementioned convertible promissory notes and other notes payable are unsecured and due on demand upon maturity. The Company may prepay the notes in whole or in part at any time. The holder of convertible notes has the option to convert some or all of the unpaid principal and accrued interest to our common voting stock.

	The total interest expense of convertible notes payable and other notes payable for the six months ended June 30, 2022 and 2021 were $34,486 and $32,775 respectively; the cumulative related accrued interest as of June 30, 2022 and December 31, 2021 were $63,159 and $28,673, respectively.

7.	Non-Current Convertible Notes Payable. As of June 30, 2022 and December 31, 2021, the amounts of non-current convertible notes payable were $27,400,000 and $0, respectively.

	APA Convertible Note

	On January 30, 2022, we issued to Ainos KY a Convertible Promissory Note in the principal amount of $26,000,000 (the “APA Convertible Note”) for the Asset Purchase Transaction as more particularly described below in Note 8. The principal sum of the APA Convertible Note is payable in cash on January 30, 2027, although we may prepay the APA Convertible Note in whole or in part without penalty. The APA Convertible Note is noninterest bearing. If not earlier repaid, the APA Convertible Note will be converted into shares of our common stock or such other securities or property for which the APA Convertible Note may become convertible, immediately prior to the closing of any public offering of our common stock if our common stock is listed on a U.S. stock exchange. The conversion price, subject to certain adjustments, will be 80% of the initial public offering price of the offering.

Table of Contents

	March 2027 Convertible Notes

	The Company issued Convertible Notes pursuant to certain Convertible Note Purchase Agreements under Regulation S. The transactions are more particularly described below:

	·	$50,000 Convertible Note issued on March 31, 2022 to Yun-Han Liao. The purchaser is the daughter of Wu Hui-Lan, the Company’s Chief Financial Officer.

	·	$850,000 aggregate Convertible Notes issued on March 28, 2022 to Chih-Cheng Tsai, Ming-Hsien Lee, Yu-Yuan Hsu, and Top Calibre Corporation, a British Virgin Islands company.

	·	$500,000 Convertible Note issued on April 11, 2022 to ASE Test Inc., a minority owner of Ainos KY.

	·	The above Convertible Notes totaling $1,400,000 are collectively referred to as the “March 2027 Convertible Notes”.

The Principal Amounts of the March 2027 Convertible Notes are payable in cash on March 30, 2027, although the Company may prepay the Convertible Notes in whole or in part without penalty. The March 2027 Convertible Notes are non-interest bearing. If not earlier repaid, the Convertible Notes will be converted into shares of common stock, $0.01 par value per share of the Company, or such other securities or property for which the Convertible Notes may become convertible, immediately prior to the closing of any public offering of the Company’s common stock if the Company’s common stock is listed on a U.S. stock exchange. The conversion price, subject to certain adjustments, will be eighty percent (80%) of the initial public offering price of any such public offering.

8.	Related Party Transactions. The following is a summary of related party transactions that met our disclosure threshold for the six months ended June 30, 2022 and 2021:

	Purchase of intangible assets and equipment

	Securities Purchase Agreement

	On April 15, 2021, we consummated a Securities Purchase Agreement with Ainos KY. Pursuant to the Securities Purchase Agreement, we issued 100,000,000 shares of common stock at $0.20 per share to Ainos KY in exchange for certain patent assignments relating to advanced testing devices and artificial intelligence consumer health care solutions, increased our authorized common stock to 300,000,000 shares and changed our name from “Amarillo Biosciences, Inc.” to “Ainos, Inc.” Immediately after consummating the transaction and issuance of the shares, Ainos KY’s ownership in the Company totaled approximately 70.30% of the issued and outstanding shares of common stock.

Table of Contents

	Asset Purchase Agreement

	Ainos KY and the Company entered into an Asset Purchase Agreement dated as of November 18, 2021 (the “Asset Purchase Agreement”), as modified by an Amended and Restated Asset Purchase Agreement dated as of January 29, 2022 (the “Amended Asset Purchase Agreement”).

	Pursuant to the Asset Purchase Agreement, we acquired certain intellectual property assets and certain manufacturing, testing, and office equipment for a total purchase price of $26,000,000 that included $24,886,023 for intangible intellectual property assets and $1,113,977 for equipment. As consideration we issued to Ainos KY a Convertible Promissory Note in the principal amount of $26,000,000 upon closing on January 30, 2022 (the “APA Convertible Note”). Refer to Note 7 for more information.

	As part of the Asset Purchase Agreement, we agreed to hire certain employees of Ainos KY who are responsible for research and development of the IP Assets and/or Equipment on terms at least equal to the compensation arrangements undertaken by Ainos KY. From and after the closing, we will have no responsibility, duty or liability with respect to any employee benefit plans of Ainos KY.

	Working Capital Advances

	All convertible and other notes payable were issued either as a result of financing or deferred compensation provided by shareholders.

	In the first half of 2021, Ainos KY provided working capital advances in the form of convertible note financing in the aggregate amount of $507,000 which bear interest at the AFR short-term rate of 1.85% and may be convertible in whole or in part at a conversion price of $0.20 per share, subject to adjustment. Dr. Stephen T. Chen ~~Chairman, CEO~~provided working capital advances in the form of convertible note and ~~President~~non-convertible note financing in the aggregate amount of $69,025 and $145,395, respectively. The convertible notes bear interest at the AFR short-term rate of 1.85% and may be convertible in whole or in part at a conversion price of $0.25 per share, subject to adjustment. A sole non-convertible note bears interest at the AFR short-term rate of 0.13%.

	In the first half of 2022, Ainos KY provided us a working capital advance in the form of a non-convertible note financing in the principal amount of $800,000, at a 1.85% per annum interest rate, maturing on February 28, 2023, and ASE Test, Inc. (the “ASE”) provided us a working capital advance in the form of a convertible note financing in the principal amount of $500,000 due on March 30, 2027 . We may prepay the convertible note in whole or in part without penalty (the “ASE Note”) before the maturity date. The ASE Note is non-interest bearing. The convertible note will automatically convert into shares of our common stock immediately prior to the closing of any public offering of our common stock if our common stock is listed on a U.S. stock exchange. The conversion price, subject to certain adjustments, will be 80% of the initial public offering price of any such public offering.

	On March 17, 2022, we executed a Promissory Note Extension with Ainos KY, pursuant to which the due dates for the convertible notes issued in 2021 to Ainos KY were extended to February 28, 2023.

	As of June 30, 2022 and December 31, 2021, the convertible and non-convertible notes payable for related parties totaled $30,855,931 and $3,505,931, respectively. Refer to Notes 6 and 7 for more information.

Table of Contents

	Purchase and sales

	Ainos COVID-19 Test Kits Sales and Marketing Agreement with Ainos KY

	On June 14, 2021, we entered into an exclusive agreement to serve as the master sales and marketing agent for the Ainos COVID-19 Antigen Rapid Test Kit and COVID-19 Nucleic Acid Test Kit with Ainos KY (the “Sales and Marketing Agreement”) which was developed by Taiwan Carbon Nano Technology Corporation (the “TCNT”), an affiliate of the Company. On June 7, 2021, the Taiwan Food and Drug Administration (the “TFDA”) approved emergency use authorization to TCNT for the Ainos COVID-19 Antigen Rapid Test Kit that will be sold and marketed under the “Ainos” brand in Taiwan. On June 21, 2022, we began marketing the Ainos SARS-CoV-2 Antigen Rapid Self-Test ("COVID-19 Antigen Self-Test Kit") under a separate EUA issued by the TFDA to TCNT on June 13, 2022. As TCNT secures regulatory authorizations from foreign regulatory agencies, the Company expects to partner with regional distributors to promote sales in other strategic markets.

	We incurred costs associated with finished goods, raw materials and manufacturing fees for Covid-19 antigen rapid test kits from TCNT pursuant to the Sales and Marketing Agreement, totaling $870,404 and $69,509 for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022 and December 31, 2021, the accounts payable to TCNT were $296,498 and $0, respectively.

	COVID-19 Antigen Rapid Test Kits Sales

	We sold Covid-19 antigen rapid test kits to ASE Technology Holding, an affiliate of the Company, ~~was exchanged~~totaling $482,359 and $121,202 for ~~a convertible promissory note.~~the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022 and December 31, 2021, the accounts receivable to ASE Technology Holding were $28,769 and $0, respectively; the payments in advance totalling $630,888 and $0, respectively.

	Product Co-development Agreement

	Pursuant to the five-year product co-development agreement (the "Product Co-Development Agreement") with TCNT, effective on August 1, 2021, we incurred development expenses totaling $374,170 and $0 for the six months ended June 30, 2022 and 2021. As of June 30, 2022 and December 31, 2021, the accrued payables were $179,547 and $65,156, respectively.

9.	Subsequent Events.

	On July 28, 2022, We granted 8,000,000 and 1,320,000 Restricted Stock Units (the “RSUs”) from our 2021 Stock Incentive Plan to employees and non-employee directors, respectively. The ~~note was executed on January 11, 2016, is payable on demand, and is unsecured. The interest rate is .75%,~~RSUs shall vest in accordance with the ~~Annual Federal Rate (AFR), the rate in effect when the note was made. The Payee, Dr. Chen, may convert all or some part~~respective employment agreements entered into by each of the ~~note~~employees and the 2021 Non-Employee Director Compensation Policy relative to the ~~Maker's (ABI's)~~non-employee directors, respectively.

	On August 8, 2022, We completed a public offering of 780,000 units on the Nasdaq Capital Market at a public offering price of $4.25 per unit (the “Offering”). Each unit issued in the Offering consists of one share of common ~~voting~~stock and one warrant to purchase one share of common stock at an exercise price of $4.25. The common stock and warrants are immediately separable and are issued separately. In addition, We sold additional Warrants to purchase up to an aggregate of 117,000 shares of our common stock in connection with the partial exercise of the over-allotment option granted to the underwriters of the Offering. We received gross proceeds of $3,316,170, before deducting underwriting discounts and commissions and other estimated offering expenses. In connection with the Offering, We effectuated a reverse split of our issued and outstanding common stock at a ratio of 1-for-15, which became effective at 8 p.m., Eastern Standard Time, on August 8, 2022. The common stock and the warrants are currently quoted on the Nasdaq Capital Market under the symbols “AIMD” and “AIMDW,” respectively. The share numbers and pricing information in this quarterly report are not adjusted to reflect the impact of the reverse stock split.

	On August 9, 2022, the APA Convertible note and the march 2027 convertible notes in the aggregate principal amount of $27,400,000 were converted into common stock at a conversion price of ~~$.168 per share.~~ 80% of the public offering price of the Offering, or $3.40, for a total of 8,058,818 shares of common stock.

On March 18, 2016, Dr. Chen purchased a Convertible Promissory Note in the amount of $262,500 through the Company's Private Placement Convertible Note Security Offering entitled Private Placement 2016-1 (previously approved by the ABI Board of Directors on March 10, 2016). The note is payable on demand, unsecured, carries interest at the Short Term Annual Federal Rate (AFR) of .65% per annum, and is convertible into ABI common stock at a price of $.1875 per share.

On June 30, 2016, a Convertible Promissory Note in the amount of $384,555 was issued to Dr. Chen in exchange for the aggregated amounts of two existing Notes Payable – Related Party. The Convertible Note is due on demand, is unsecured, bears interest at the Short-Term Applicable Federal Rate of .64% per annum, and is convertible into ABI common stock at a stock price of $.1875 per share.

On May 25 2017, a Convertible Promissory Note in the amount of $70,000 was issued to Dr. Chen in exchange for the aggregated amounts of three cash advances. The Convertible Note is due on demand, is unsecured, bears interest at the Short-Term Applicable Federal Rate of .86% per annum, and is convertible into ABI common stock at a stock price of $.1875 per share.

On September 1 2017, a Convertible Promissory Note in the amount of $25,000 was issued to Dr. Chen in exchange for one cash advance. The Convertible Note is due on demand, is unsecured, bears interest at the Short-Term Applicable Federal Rate of .96% per annum, and is convertible into ABI common stock at a stock price of $.1875 per share.

September 30, 2017 December 31, 2016
Convertible Note payable – related party $ 144,426 $ 144,426
Convertible Note payable – related party 262,500 262,500
Convertible Note payable – related party 384,555 384,555
Convertible Note payable – related party 70,000 -
Convertible Note payable – related party 25,000 -
Convertible Notes payable – related party $ 886,481 $ 791,481

~~Related Party Transactions.~~ On May 23, 2016, Amarillo Biosciences, Inc. ("ABI"), the Principal, entered into an Agency and Service Agreement with ACTS Global Healthcare, Inc. ("ACTS Global"), a Taiwan Corporation, the Agent. To date, ABI has advanced to ACTS Global "Principal Funds"

Additionally, convertible promissory notes held by Ainos KY in the aggregate principal amount of NTD $3,000,681 ($91,968 USD), to be utilized and /or expended by ACTS Global solely as instructed by ABI. Pursuant to the Agreement, additional advances may be made by ABI to ACTS Global. An advance in the amount$3,000,000 plus accrued interest of ~~$37,500 was made to ACTS Global~~$42,959 were converted into common stock on ~~September 1, 2017. ACTS Global was also engaged by ABI to perform such other business services as may be requested by ABI in the agreed geographic area~~August 8, 2022, at a conversion price of ~~Taiwan and the People's Republic~~$0.20, for a total of ~~China. That Agency Agreement is still in force. For their services, ACTS Global, is to be paid by ABI, one percent (1%)~~1,014,319 shares of ~~the Principal's services expended by the Agent at the Principal's direction. Any other services rendered by the Agent will be paid for by the Principal based on comparable and/or reasonable values~~common stock.

Table of the service rendered. As of September 30, 2017, ACTS Global has a balance of $28,584 to be utilized for the benefit of the Company, which is included on the Company's Balance Sheet in Advance to related party.Contents

In April 2016, the Company received proceeds of $187,500 from an investor related to Amarillo Biosciences (Hong Kong) Ltd. in exchange for the potential issuance of 1,000,000 shares of common stock (Private Placement 2016-2). As of September 30, 2017, the shares have not been issued and the amount received is included in Advances from related party. As of the filing date, the stock subscription has not been executed.

On December 20, 2016, effective January 1, 2017, the Board of Directors approved a resolution whereby Dr. Chen's annual compensation was changed to $90,000 cash per annum and $75,000 per annum payable in the Company's unregistered, voting common stock. The Board also approved the change in compensation to Bernard Cohen to $65,000 cash per annum and $10,000 per annum payable in the Company's unregistered, voting common stock. The cash compensation is to be paid on the normal payroll cycle of 15th and 31st of each month and stock compensation to be paid quarterly. Shares are to be priced at the average of all trading day closing quotes on the OTC-BB for the month preceding date of issuance, with such shares to be issued on the first business day after the close of each calendar quarter or as soon thereafter as practicable. During the period ended September 30, 2017, the Company has issued an aggregate of 535,525 shares of common stock valued at $122,500. As of September 30, 2017, the Company has accrued $21,250 in Accounts Payable and Accrued Expenses representing Q3 2017 shares that have not been issued.

On September 29, 2017, the Company wired cash funds in the amount of $13,000 to CTBC Bank Co Ltd in Taipei, Taiwan for the purpose of funding a cash account for the Company to begin direct branch business operations in the country. The minimum deposit amount required to open the account was NTD 300,000 which at the time was equivalent to $10,000 (USD). The Company wired $13,000 to the bank to minimize currency translation risk and to cover all necessary fees deducted from the transfer leaving the minimum amount required to open such an account in Taiwan for foreign branch operations.

7.	~~Subsequent Events~~

On October 6, 2017, Stephen T. Chen, CEO, and Bernard Cohen, CFO/VP, received 68,731 shares of common stock and 9,164 shares of common stock, respectively, as payment of a Q3 2017 stock bonus totaling $21,250. The stock was issued at a price of $.2728 per share. $21,250 was accrued and recognized as stock compensation expense for the quarter ended September 30, 2017.

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our financial statements and the notes thereto which appear elsewhere in this report. The results shown herein are not necessarily indicative of the results to be expected in any future periods.

~~Forward-Looking Statements: Certain~~

Some of the statements ~~made throughout~~in this ~~document~~report are ~~"forward-looking statements"~~“forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of ~~1995 (the "Act").~~1995. Forward-looking statements include ~~without limitation, any statement~~statements regarding our current beliefs, goals and expectations about matters such as our expected financial position and operating results, our business strategy and our financing plans. The forward-looking statements in this report are not based on historical facts, but rather reflect the current expectations of our management concerning future results and events. The forward-looking statements generally can be identified by the use of terms such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “foresee,” “may,” “guidance,” “estimate,” “potential,” “outlook,” “target,” “forecast,” “likely” or other similar words or phrases. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may ~~predict, forecast, indicate~~cause our actual results, performance or ~~imply~~achievements to be different from any future results, performance and achievements ~~costs~~expressed or ~~expenses~~implied by these statements. We cannot guarantee that our forward-looking statements will turn out to be correct or that our beliefs and ~~may contain words such as "believe," "anticipate," "expect," "estimate," "project," "budget," or words or phrases~~goals will not change. Our actual results could be very different from and worse than our expectations for various reasons. These forward-looking statements are not guarantees of ~~similar meaning. Forward-looking statements~~future performance and involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data, or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all).

The following factors, among others, could cause actual results and future events to differ materially from those ~~projected~~set forth or contemplated in the

forward-looking ~~statements. Such risks~~statements:

Table of Contents

	·	the extent and duration of the COVID-19 pandemic and the impact of the end of the COVID-19 pandemic on our business and our expectations regarding customer and user demand for our COVID-19 test kits;
	·	possible changes in capital structure, financial condition, future working capital needs and other financial items;
	·	our expectations of the reliability, accuracy and performance of our products and services;
	·	our ability to obtain additional funds for our operations;
	·	unforeseen changes in the course of research and development activities and in clinical trials;
	·	our ability to obtain and maintain regulatory authorizations, clearances or approvals for our tests and other product candidates, including EUAs (“Emergency Use Authorizations”) for our COVID-19 test kits or other product candidates;
	·	our ability to successfully build out our sales and marketing infrastructure, the costs and success of our marketing efforts, and our ability to promote our brand;
	·	our ability to establish demand for our products and services and expand geographically;
	·	our intellectual property position and our expectations regarding our ability to obtain and maintain intellectual property protection;
	·	our ability to effectively manage our expected growth, including our ability to retain and recruit personnel, and maintain our culture;
	·	possible changes in cost, timing and progress of development, preclinical studies, clinical trials and regulatory submissions;
	·	the rate and degree of market acceptance of any approved product candidates;
	·	the impact of applicable U.S., Taiwanese and international laws and regulations; and
	·	our ability to implement, maintain and improve effective internal controls and remediate material weaknesses.

Any forward-looking statements in this report are made only as of the date hereof and, ~~uncertainties are detailed from time~~except as may be required by law, we do not have any obligation to ~~time~~publicly update any forward-looking statements contained in ~~reports~~this report to reflect subsequent events or circumstances.

For a further discussion of these and other factors that could impact our future results, performance or transactions, see Part I, Item 1A (Risk Factors) of our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2021 filed ~~by the Company~~ with the ~~Securities~~SEC on April 15, 2022.

Overview

Ainos, Inc., a Texas corporation formerly known as Amarillo Biosciences, Inc. (the "Company", "we" or "us"), is engaged in developing medical technologies for point-of-care (“POCT”) testing and ~~Exchange Commission, including Forms 8-K, 10-Q~~safe and 10-K and include among others the following: promulgation and implementation of regulations by the U.S. Food and Drug Administration ("FDA"); promulgation and implementation of regulations by foreign governmental instrumentalities with functions similar to those of the FDA; costs of research and development and trials, including without limitation, costs of clinical supplies, packaging and inserts, patient recruitment, trial monitoring, trial evaluation and publication; and possible difficulties in enrolling a sufficient number of qualified patientsnovel medical treatment for ~~certain clinical trials. The Company is also dependent upon~~ a broad range of disease indications. Since our inception in 1984, we have concentrated our resources on business planning, raising capital, research and clinical development activities for our programs, securing related intellectual property and commercialization of proprietary therapeutics using low-dose non-injectable interferon (“IFN”). In addition to our core IFN technology, we are committed to developing a diversified healthcare business portfolio to include medical devices and consumer healthcare products.

Although we have historically been involved in extensive pharmaceutical research and development of low-dose oral interferon as a therapeutic, we are prioritizing the commercialization of medical devices as part of our diversification strategy. Since the beginning of 2021, we have acquired significant intellectual property from our majority shareholder, Ainos, Inc., a Cayman Islands corporation (“Ainos KY”), to expand our potential product portfolio into Volatile Organic Compounds (“VOC”) and COVID-19 POCTs. We expect our underlying intellectual property to enable us to expedite the commercialization of our medical device pipeline, beginning with Ainos-branded COVID-19 POCT product candidates.

Table of Contents

Our portfolio of products

Our portfolio of products is currently comprised of the following:

	·	COVID-19 Antigen Rapid Test Kit and Ainos’ Cloud-based Test Management Apps. Our cloud-based test management platform is comprised of an antigen rapid test kit, a personal application, or app, and an enterprise app. We anticipate our management apps will allow individuals and organizations to seamlessly manage tests, trace infections, and share results. As the first commercialized COVID-19 product we sell, we currently market the Ainos COVID-19 antigen rapid test kit in Taiwan under emergency use authorization (“EUA”) issued by the Taiwan Federal and Drug Administration (“TFDA”) in 2021. We market the Ainos COVID-19 antigen rapid test kit under our brand name. The kit is manufactured by TCNT, our product co-developer.

	·	COVID-19 Nucleic Acid Test. Our solution consists of a color-changing assay that is compatible with standard Polymerase Chain Reaction (“PCR”) machines and delivers test results within 40 minutes. In addition to our assay’s compatibility with existing PCR equipment, we will also offer portable, low-cost test equipment intended to help medical professionals quickly scale testing capacity. We will market the product under the Ainos brand name, and our co-developer TCNT will manufacture the product.

	·	VOC POCT – Ainos Flora. Our Ainos Flora device will perform a non-invasive test for female vaginal health and certain sexually transmitted diseases (“STDs”) including vaginitis, gonorrhea and trichomoniasis, within a few minutes. We expect Ainos Flora will provide convenient, discreet, rapid testing in a point-of-care setting which will allow women to self-test at home.

	·	VOC POCT – Ainos Pen. Our Ainos Pen device is a cloud-connected, multi-purpose, portable breath analyzer that is intended to monitor health conditions including oral, gastrointestinal, liver, and renal health within minutes. We expect consumers to be empowered to share their self-test results with their physicians through in-person and telehealth medical consultations.

	·	VOC POCT – CHS430. The CHS430 device is intended to provide non-invasive testing for ventilator-associated pneumonia within 10 minutes, as compared to current standard of care invasive culture tests that typically take more than two days to provide results. We plan to be the exclusive sales agent for CHS430, pursuant to our Product Development Agreement with our co-developer, TCNT, who will manufacture the product.

	·	Very Low-Dose Oral Interferon Alpha (“VELDONA”). VELDONA is a low-dose oral interferon alpha (“IFN-α”) formulation based on our nearly four decades of research on IFN-α’s broad treatment applications. We have conducted a parallel study based on VELDONA alone and joint study with InnoPharmax, Inc. for the treatment of COVID-19 and other potential viral infections. We have also recently completed our own animal studies for the same treatment and subsequently are now conducting studies based on the VELDONA-only program.

	·	Synthetic RNA (“SRNA”). We are developing a SRNA technology platform in Taiwan. Our initial focus is to develop a potential COVID-19 mRNA vaccine platform using the full-length spike or the RBD gene sequence of the alpha and delta variants as reference sequences.

An integral part of our operating strategy is to create multiple revenue streams through commercializing our product portfolio and leveraging our intellectual property patents, including potentially out-licensing or forming strategic relationships to develop our medical devices, consumer healthcare products and low-dose interferon therapeutics.

Table of Contents

In 2022, we are prioritizing the commercialization of our POCT devices, beginning with seeking EUA authorizations for the COVID-19 POCT product candidates and plans to commercialize our other POCT product candidates. As a general ~~economic~~strategy, we plan to conduct clinical trials in Taiwan and ~~financial risks, such as possible increases~~use the data to apply for TFDA approval and FDA clearance via the 510(k) or comparable pathway. If our products are approved, we plan to work with third-party distributors to market our products in countries where we receive regulatory approval and to seek various business relationships with other medtech companies to market our products. At the ~~costs~~same time, we plan to initiate clinical trials for the VELDONA and SRNA programs over the course of ~~employing and/or retaining qualified personnel and consultants and possible inflation which might affect the Company's~~this year.

Our ability to ~~remain within its budget forecasts. The principal uncertainties~~generate product revenue sufficient to ~~which the Company is presently subject are its inability to ensure that the results of trials performed by the Company~~achieve profitability will ~~be sufficiently favorable to ensure eventual regulatory approval for commercial sales, its inability to accurately budget at this time the possible costs associated with hiring~~depend on further successful development and ~~retaining of additional personnel, uncertainties regarding the terms and timing~~commercialization of one or more ~~commercial partner agreements~~of our current or future product candidates and ~~its ability~~programs. We anticipate our POCT products candidates to potentially generate organic cash flows to support our business while we invest in our other pipeline projects. We expect to continue to incur significant expenses for the next few years as we advance our product candidates through preclinical development, clinical trials and regulatory approval. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution, and legal and regulatory compliance. We may also incur expenses in connection with strategic relationships for the development of additional product candidates. Furthermore, we expect to continue to incur costs associated with operating as a ~~going concern.~~

~~The risks cited here are not exhaustive. Other sections of this report~~public company, including significant legal, accounting, investor relations and other expenses.

Until we can generate significant revenue from product sales, if ever, we expect to finance our operations with business revenues and proceeds from external sources. We may pursue additional funding that may include our entry into or expansion of borrowing arrangements; research and development incentive payments, government grants, co-financing from pharmaceutical companies and other corporate sources; and potential future collaboration agreements with pharmaceutical companies or other third parties. We may be unable to raise additional ~~factors which could adversely impact~~funds or enter into such other agreements or arrangements when needed on favorable terms. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the ~~Company's business~~development and ~~future operations. Moreover, the Company is engaged in a very competitive and rapidly changing industry.~~

~~New risk factors emerge from time to time and it is not possible~~commercialization, potential in-licenses or acquisitions plans for ~~management~~one or more of our product candidates.

We are unable to predict ~~all such risk factors, nor can it assess~~ the ~~impact~~timing or amount of ~~all such risk factors on~~unexpected expenses or when or if we will be able to achieve or maintain profitability due to the ~~Company's business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those projected in any forward-looking statements. Given these~~numerous risks and uncertainties ~~investors should~~associated with product development and related legal regulatory requirements. When we are eventually able to generate additional product sales, those sales may not ~~place undue reliance~~be sufficient to become profitable. If we fail to become profitable or are unable to sustain profitability on ~~forward-looking statements as~~ a ~~prediction~~continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

As of ~~actual future events.~~

~~Overview.~~ ~~ABI has been (and is) engaged~~June 30, 2022, we had available cash and cash equivalents of $1,753,877. We anticipate business revenues and further potential financial support from external sources to fund our operations over the next twelve months. We have based this estimate on assumptions that may prove to be incorrect and we could exhaust our available capital resources sooner than we expect. See “Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources” for additional information. To finance our continuing operations, we will need to raise additional capital, which cannot be assured.

Impact of COVID-19 on Our Business

The COVID-19 pandemic presented us an opportunity to grow our business. Substantially all of our operating revenue came from the sale of the Ainos COVID-19 antigen rapid test kits in Taiwan. We intend to broaden our market reach if TCNT, our product co-developer and manufacturing partner, successfully obtains regulatory clearance in the ~~business of biopharmaceutical research and development. Its primary focus historically has been the development of low-dose, orally administered interferon. ABI holds~~U.S. or ~~licenses various patents; it also is the developer of Maxisal~~^®~~, a dietary supplement to treat dry-mouth symptoms.~~

Having successfully reorganized, the Company's goal continues to be the expansion of the reach of its research, development, and marketing of biopharmaceutical, biotechnical, health and life science related products. ABIother countries.

Table of Contents

We believe affordable, easy-to-use, rapid COVID-19 testing will continue to leverage its core technology going forward by using its thirty years of scientific and clinical data to establish interferon-alpha lozenges as a therapeutic agent for conditions such as influenza, hepatitis C, and various causes of thrombocytopenia just to name a few. The Company is committed to expanding its business operations from the currently narrow focus to encompass a wide variety of licensing, partnerships, and development opportunitiesbe in demand at least in the ~~aforementioned sectors. This commitment extends not only~~short-term. We anticipate our management apps, when used with the Ainos antigen rapid test kit, will allow individuals and organizations to effectively manage tests, trace infections, and share results. We also anticipate the Ainos COVID-19 nucleic acid test can help medical professionals quickly scale testing capacity if the product receives regulatory clearance.

We are continuing to monitor the potential impact of the pandemic, but we cannot be certain the future impact on our business, financial condition, results of operations and prospects. Depending on developments relating to the ~~U.S., but~~pandemic, including the emergence of new variants, the pandemic may affect our ability to ~~Taiwan, China,~~initiate and ~~other Asian Countries.~~

~~ABI holds various patents and related intellectual property, which are described earlier in this document. The most significant asset is intellectual property consisting of five patents, four in~~complete research studies, delay the ~~U.S. and one in Taiwan. Additionally, we have one trademark. One of the patents expires in four months and two of the patents expire in a range of two to four years. The newest patents will expire~~

~~in April and May 2033. Four out~~initiation of our ~~five patents employ the Company's core technology, which is the oral, low dosage use~~future research studies, disrupt regulatory activities or have other adverse effects on our business, results of ~~(human) interferon. These patents will not have significant value unless commercialized, which will require adequate funding, time, effort,~~operations, financial condition and expertise in biologics. As previously stated, ABI's sole source of human interferon discontinued production, which negatively impacted ABI's ability to obtain source product. The anticipated location and development time required for a new source of human interferon along with the requisite testing and FDA approval time could exceed the life span of all but the newest of the patents, and even if it does not, could leave relatively little time to derive revenues from the patent protections, prior to patent expiration. The patent which also carries the trademark, a product promoting oral health, also is the victim of supply-chain interruption because the supplier of the raw material for the product (anhydrous crystalline maltose, or ~~"ACM") has substantially increased its purchase price. The price increase and other actions have rendered the manufacture and sale of the product less attractive.~~

It is anticipated that ABI will attempt to monetize and commercialize its existing intellectual property, which would necessitate identification and acquisition of new source product (e.g., Interferon), conducting new trials, and additional protection of intellectual property. It is estimated this may require additional funding (including general administrative cost and professional fees) of between $500,000 and $800,000. Similarly, ABI may explore the acquisition and development of new product lines. The cost to commercialize any such development could likely require a similar funding level, resulting in aggregate funding requirements between $1 million and $1.6 million. These activities, even if undertaken, would not be expected to produce meaningful revenue before the last calendar quarter of 2018, or possibly later.

prospects.

Results of Operations for ~~Quarters~~Quarter Ended ~~September~~June 30, ~~2017~~2022 (“Q2 2022”) and ~~2016:~~

~~Revenues. During~~June 30, 2021 (“Q2 2021”):

Revenues, Cost and Gross Profit. The Company reported revenue of $636,627 and $202,992 in Q2 2022 and Q2 2021, respectively from product sales of the ~~quarter ended September 30, 2017, no revenue was recognized nor was any recognized for the quarter ended September 30, 2016.~~

~~Cost of Revenues. No~~Ainos COVID-19 Antigen Rapid Test Kits in Taiwan. The cost of ~~revenue~~sales relating to product sales of the Ainos COVID-19 Antigen Rapid Test Kits in Q2 2022 was ~~recognized during~~$318,963 compared to of Covid-19 Test Kits $69,508 in Q2 2021. Gross profit from product sales in Q2 2022 was $317,664 as compared to $133,484 in Q2 2021. Gross profits generated from product sales of the ~~quarters ended September 30, 2017 or 2016~~

Ainos COVID-19 Antigen Rapid Test Kits increased by $184,180 between Q2 2022 and the same quarter in the previous year.

Research and Development Expenses. ~~Research~~ R&D expenses in Q2 2022 were $1,634,856 mainly consisting of amortization expense of intellectual property assets, staffing and co-development research. There were no R&D expenses during the same quarter in 2021. We expect that our R&D expenses will increase over time as we further product development ~~expenses have not been incurred~~of our POCT and other product candidates. In addition to increasing our in-house R&D staffing, we also contribute R&D funding under our co-development agreements with Taiwan Carbon Nano Technology (“TCNT”), our manufacturing collaborator and our affiliate company for ~~the quarters ended September 30, 2017, and September 30, 2016.~~

POCT products.

Selling, General and Administrative Expenses. Selling, general and administrative expenses in Q2 2022 were $627,104 mainly consisting of staffing and legal, audit and consulting etc. professional service expenses, and in Q2 2021 were $860,030 mainly consisting of amortization expense of intellectual property assets, staffing and legal, audit and consulting etc. professional service expenses. Although personnel expenditure increased in Q2 2022, the total S&A expenses decreased by $232,926 (27%) compared with Q2 2021.The decrease was mainly due to the amortization expense of intellectual property assets, as these amortization expense has been charged to the R&D department after establishing R&D department in August 2021; besides, one-time transactional expenses such as the Securities Purchase Agreement transaction and initiation of new operational activities only incurred in 2021.

Operating Loss. The Company's operating loss was $1,944,295 and $726,546 in Q2 2022 and Q2 2021, respectively, reflecting a $1,217,749 (168%) increase in operating losses between the reporting periods. As stated in our discussion about R&D expenses, our operating losses are mainly attributable to additional R&D expenses in line with the Company's product development initiatives.

Interest Expense. In Q2 2022 interest expense was $18,796 compared to $20,981 in Q2 2021, due to accrued interest for convertible and other debt notes amounted to $ 4,389,931 and $1,711,420 as of June 30, 2022 and 2021, respectively. The interest of $20,981 in Q2 2021 including the default interest of the principal due and unpaid, and the holders of those notes waived their right to such default interest in Q3 2021.

Table of Contents

Net Loss. Net loss attributable to common stock shareholders was $1,954,032 in Q2 2022 compared to $749,774 in Q2 2021, resulting in a 1,204,258 (161%) increase in net losses. The net losses are attributable to increased R&D expenses in line with the Company's product development plans.

Results of Operations for the Six Months Ended June 30, 2022 (“H1 2022”) and June 30, 2021(“H1 2021”):

Revenues. The total revenue recognized from the sale of Covid-19 Test Kits in Taiwan was $723,828 through June 30, 2022, as compared to $205,113 for the first six months of 2021, an increase of $518,715 or 253%.

Cost of Revenues and Gross Profit. Cost of sales of Covid-19 Test Kits for the six months ended June 30, 2022 was $360,042 compared to $70,757 for the six months ended June 30, 2021. The increase in cost of sales of Covid-19 Test Kits for 2022 as compared to 2021 for the six month period was $289,285, or 409 %. Gross profit for six months ended June 30, 2022 was $363,786 compared to $134,356 for the six months ended June 30, 2021, an increase of $229,430 or 171%.

Research and Development Expenses. Research and developmentexpenses of $3,212,310 were incurred for the first six months of 2022, compared to $0 for the first six months of 2021, an increase of $3,212,310. The increase in 2022 was primarily due to amortization expense of intellectual property assets, staffing and co-development research. In addition, we also contributed R&D funding to our COVID-19 oral treatment program.

Selling, General and Administrative Expenses. Selling, general and administrative expenses of ~~$230,875~~$1,178,834 were incurred for the ~~third quarter~~first six months of ~~2017,~~2022, compared to ~~$178,470~~$1,383,011 for the ~~third quarter~~first six months of ~~2016, an increase~~2021, a decrease of ~~$52,404 (29%~~$204,177 (15%). ~~This increase is mostly due~~The mainly S&A expenses of H1 2022 and H1 2021 are the same as Q2 2022 and Q2 2021, and the reasons for expenses decrease are also the same. Please refer to ~~additional salary expense, stock compensation expense, fundraising fees, and professional fees~~the analysis in ~~2017.~~

preceding paragraph.

Operating Loss. In the ~~three-month~~six month period ended ~~September~~June 30, ~~2017,~~2022, the ~~Company experienced and~~Company's operating loss ~~of $230,875~~was $4,027,358 compared to an operating loss for the ~~three-month~~six month period ended ~~September~~June 30, ~~2016~~2021 of ~~$178,470,~~$1,248,655, a ~~$52,404 increase~~$2,778,703 (223%) increase. Our operating losses are mainly attributable to additional R&D expenses in ~~loss. The increased expenses of $52,404 in~~line with the ~~third quarter of 2017 over 2016 account for the loss.~~

Company's product development initiatives.

Interest Income and Expense. ~~During the three-month period ended September 30, 2017, interest~~ Interest expense, net was $1,929, compared to $798 for the three-month period ended September 30, 2016, an increase of $1,131 for the period. The interest expense recognized in the third quarter of 2017 is mostly due to accrued interest for our convertible loans made by Dr. Stephen Chen.

Net Loss. In the three-month period ended September 30, 2017, the Company experienced net loss of $232,804 compared to a net loss for the three-month period ended September 30, 2016, of $179,268 a $53,536 (30%) increase in loss. This increase in loss was mainly due to increased expenses and lack of revenue for the period.

~~Results of Operations for the Nine Months Ended September 30, 2017 and 2016:~~

Revenues. During the nine months ended September 30, 2017 and September 30, 2016, there were sales of APT equipment and receipt of a sales commission for sale of a natural resource product of $250,502 and $4,400, respectively. There were no other sources of revenue for the period. No medicinal herbs were sold in 2017 as there were in 2016, $4,400. The significant increase in revenue for the nine-month period in 2017 over the same period in 2016, was due to the sale of APT equipment. The net increase for the period ended September 30, 2017 was $246,102 over the same period in 2016,

Cost of Revenues. During the nine months ended September 30, 2017, the cost of revenues was $58,801 and for September 30, 2016, $5,100. The cost of revenues for the period ended 2017 resulted from the purchase of APT equipment. No other merchandise was purchased for sale. The increase in cost of revenue for 2017 over 2016 was $53,701. The large percentage increase for the comparative periods was due to the high cost nature of APT equipment versus any other products historically purchased. Gross profit for September 2017 increased $192,401 over the same period in 2016 because of the strong margins available on APT equipment.

~~Research and Development Expenses. Research and development expenses have not been incurred~~$35,483 for the six months ended ~~September~~June 30, ~~2017, and September 30, 2016.~~

~~Selling, General and Administrative Expenses. Selling, general and administrative expenses of $592,822 were incurred~~2022, compared to $32,879 for the ~~first nine~~six months of 2017, compared to $434,176 for the first nine months of 2016, an increase of $158,646 (37%). This increase is mostly due to additional salary expense, stock compensation expense, fundraising fees, and professional fees in 2017 not incurred in 2016.

~~Operating Loss. In the nine month period ended September 30, 2017, the Company's operating loss was $401,121 compared to an operating loss for the nine month~~ period ended June 30, 2016 of $434,876, $33,755 (8%) less than the loss for the previous year. Although expenses increased in 2017 over 2016, the increased gross margins significantly reduced the negative impact of the expense increases for the period.

~~Interest Expense. During the nine-month period ended September 30, 2017,~~2021. The interest expense was ~~$7,630, compared~~due to ~~$2,257~~the interest-bearing debt, including convertible notes and other debt notes, amounted to $4,389,931 and $1,711,420 as of June 30, 2022 and 2021, respectively. The interest of $32,879 in H1 2021 including the default interest of the principal due and unpaid, and the holders of those notes waived their right to such default interest in Q3 2021.

Net Loss. The Net Loss for the ~~nine-month period ended June 30, 2016,~~first half of 2022, increased to $4,053,927 from $1,283,781 in 2021, an increase of ~~$5,373 (238%~~$2,770,146 (216%). for the period. The ~~interest expense recognized~~major constituents of the increase in net loss are the increases in R&D expenses in the ~~nine-month period ended September~~first six months of 2022.

Liquidity and Capital Resources

As of June 30, ~~2017 is mostly due to accrued interest for convertible loans from Dr. Stephen Chen~~2022 and ~~interest paid associated with our D&O insurance policy payment.~~

~~Net Loss. In~~December 31, 2021, the nine months ended September 30, 2017, the Company's net loss was $408,751 compared to a net loss for the nine months ended September 30, 2016 of $437,133 a decrease in loss of $28,382 (6%). This decrease was mainly due to recognition of APT equipment revenue for the nine months and the resulting increase in Gross Profit.

~~Liquidity Needs. At September 30, 2017, we~~Company had available cash of ~~$145,029 whereas we had a~~$1,753,877 and $1,751,499, respectively.

Table of Contents

The following table summarizes our cash ~~position of $134,125 as of December 31, 2016. The Company had a working capital deficit of $1,010,176~~flows at the end of ~~September~~June 30, ~~2016. For 2017, the September 30, working capital deficit was $1,189,114. Historically the burn rate was between $50,000~~2022:

	Six Months Ended June 30,
	2022			2021
Net cash used in operating activities		(1,619,153	)		(42,926	)
Net cash used in investing activities		(424,557	)		(23,276	)
Net cash provided by financing activities		2,189,875			650,595

Operating activities:

Cash used by operating activities increased in H1 2022 compared to H1 2021, due to higher operating expenses. We incurred net operating outflow of $1,619,153 for H1 2022 and ~~$60,000 per month. It is difficult~~$42,926 for H1 2021. While our revenues grew in H1 2022 due to ~~estimate the burn rate at this point insomuch as the new budgets and new projects are being developed. One~~sales of the ~~Company's main goals is~~Ainos COVID-19 test kits, our increased staffing and investment in research and developments increased our expenses resulted in higher net operating outflow.

Investing activities:

Cash used in investing activities increased in H1 2022 compared to ~~return~~cash used in H1 2021, attributed to the ~~status~~acquisition of R&D equipment and office facilities.

Financing activities:

Cash provided by financing activities increased in H1 2022 compared to cash provided in H1 2021, which primarily reflects higher proceeds from convertible notes payable amounted to $1,400,000 and other non-convertible notes payable amounted to $800,000. For a ~~going concern by having reduced operating losses~~discussion of the notes, see “Part II, Item 2 - Unregistered Sales of Equity Securities and ~~subsequently becoming profitable.~~ Use of Proceeds.”

As ~~indicated throughout this document, two other major goals~~ of ~~ABI~~June 30, 2022, the principal amount of our convertible and non-convertible notes payable due within the next 12 months was $3,376,526 and $1,013,405, respectively.

The convertible notes outstanding in the principal amount of $3,000,000 due in February 2023 are convertible at the option of the holder at a conversion price of $0.20. The non-convertible debt outstanding in the principal amount of $213,405 are currently payable and due on demand and the rest of amount $800,000 due in March 2023.

On January 30, 2022, we issued a non-interest bearing Convertible Promissory Note in the principal amount of $26,000,000 (the “APA Convertible Note”) in connection with the closing of the Asset Purchase Agreement.

In addition, in the first quarter of 2022, we executed $1,400,000 of the March 2027 Convertible Notes with terms that are substantially similar to ~~(1) leverage~~ the ~~core~~terms of the APA Convertible Note.

In 2022 we intend to focus on commercializing our POCT medical devices and developing our VELDONA-based COVID-19 oral treatment program. Our near-term liquidity requirements will include expenses for clinical trials, repayment of debt not converted into equity, regulatory clearances, and marketing to commercialize our POCT devices, including the Ainos COVID-19 Nucleic Acid Test, the Ainos Flora, the Ainos Pen and our VELDONA-based COVID-19 oral treatment program. We also intend to increase staffing for general administration, marketing and technology ~~low-dose oral interferon,~~development purposes.

Table of Contents

In 2023 and ~~(2) diversify Company operations~~beyond, we intend to ~~incorporate additional lines of business which will extend the reach of ABI into additional economic sectors~~invest in research and development and clinical trial spending to advance our VELDONA development efforts for disease indications such as ~~biotech / bio-pharmaceutical / health care products~~thrombocytopenia and ~~life sciences business. Our investor group~~Sjögren’s syndrome. We also plan on investing in clinical trials and regulatory approval for the CHS430 device, in collaboration with TCNT, and clinical trial expenses for our SRNA program.

On August 9, 2022, in connection with the Offering, (i) the APA Convertible Note, (ii) the March 2027 Convertible Notes and (iii) $3,000,000 aggregate principal amount of convertible notes plus accrued interest of $42,959 were converted into a total of 9,037,137 shares of our common stock. Following the closing of the Offering on August 11, 2022, we received net proceeds of approximately $2.1 million.

The Company anticipates that its cash reserves, business revenues from the Ainos COVID-19 test kits, sales of its common stock, and debt financing through convertible and non-convertible notes are sufficient to fund the Company’s operations over the next twelve months. As the number of reported COVID cases has ~~indicated~~been increasing in Taiwan, we anticipate demand for the ~~willingness~~test kits to assist in future financing of operations as ABI seeks to monetize its existing (and potentially newly developed) intellectual property. ABI estimates its financing needs to be between $1,000,000 and $1,600,000 to support our core technology, which is includedincrease, at least in the ~~Pharmaceutical Division, and exploring the possibility of instituting new revenue streams with a Medical Division and a Consumer Products Division.~~

short term. There can be no assurance that we will be successful in our efforts to make the Company profitable. If those efforts are not successful, ~~we will be forced to cease operations.~~

Forward-Looking Statements: Certain statements made throughout this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance, achievements, costs or expenses and may contain words such as "believe," "anticipate," "expect," "estimate," "project," "budget," or words or phrases of similar meaning. Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from those projected in the forward-looking statements. Such risks and uncertainties are detailed from time to time in reports filed by the Company ~~with~~may raise additional capital through the ~~Securities~~issuance of equity securities, debt financings or other sources in order to further implement its business plan, including, as required, additional external financing from our majority shareholder. However, if such financing is not available when needed and Exchange Commission, including Forms 8-K, 10-Q and 10-K and include among others the following: promulgation and implementation of regulations by the U.S. Food and Drug Administration ("FDA"); promulgation and implementation of regulations by foreign governmental instrumentalities with functions similar to those of the FDA; costs of research and development and trials, including without limitation, costs of clinical supplies, packaging and inserts, patient recruitment, trial monitoring, trial evaluation and publication; and possible difficulties in enrolling a sufficient number of qualified patients for certain clinical trials. The Company is also dependent upon a broad range of general economic and financial risks, such as possible increases in the costs of employing and/or retaining qualified personnel and consultants and possible inflation which might affect the Company's ability to remain within its budget forecasts. The principal uncertainties to which the Company is presently subject are its inability to ensure that the results of trials performed byat adequate levels, the Company will ~~be sufficiently favorable~~need to ~~ensure eventual regulatory approval for commercial sales,~~reevaluate its inability to accurately budget at this time the possible costs associated with hiring and retaining of additional personnel, uncertainties regarding the terms and timing of one or more commercial partner agreements and its ability to continue as a going concern.

The risks cited here are not exhaustive. Other sections of this report may include additional factors which could adversely impact the Company's business and future operations. Moreover, the Company is engaged in a very competitive and rapidly changing industry.

New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the Company's business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those projected in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual future events.

operating plan.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk.

As a ~~"smaller~~“smaller reporting ~~company",~~company,” we are not required to provide the information under this Item 3.

ITEM 4. Controls and Procedures

Disclosure Controls and Procedures

At the end of the period covered by the Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and this Form 10-Q Quarterly Report for the quarter ending September 30, 2017, an evaluation was carried out under the supervision of and

Our management, with the participation of our ~~management, including the~~ Chief Executive Officer ~~("CEO")~~ and Chief Financial Officer, ~~("CFO"), of~~evaluated the effectiveness ~~of the design and operations~~ of our disclosure controls and procedures ~~(as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). Based on that evaluation, the CEO and the CFO have concluded that~~ as of the end of the period covered by ~~the Annual Report~~this report. Based upon that evaluation, our Chief Executive Officer and ~~Quarterly Report,~~Chief Financial Officer concluded that our disclosure controls and procedures were ~~not~~ effective as of June 30, 2022. The term “disclosure controls and procedures,” as defined in ~~ensuring that: (i)~~Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by usa company in the reports that ~~we file~~it files or ~~submit to the SEC~~submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in ~~applicable~~the SEC’s rules and ~~forms~~forms. Disclosure controls and ~~(ii) material~~procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in ~~our~~the reports ~~filed~~that it files or submits under the Exchange Act is accumulated and communicated to ~~our~~the company’s management, including ~~our CEO~~its principal executive and ~~CFO,~~principal financial officers, as appropriate to allow ~~for accurate and~~ timely decisions regarding required disclosure.

~~Changes to~~

Internal ~~Controls and Procedures over~~Control Over Financial Reporting

There were no changes in our internal controls over financial reporting that occurred during the quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

~~Management's Remediation Plans~~

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, ~~to provide reasonable assurance regarding~~as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). As previously disclosed in our Form 10-K/A for the ~~reliability~~year ended December 31, 2021, under the supervision and with the participation of ~~financial reporting~~our management, including our Chief Executive Officer and ~~the preparation~~Chief Financial Officer, we conducted an evaluation of ~~financial statements for external purposes in accordance with generally accepted accounting principles ("GAAP"). Management has assessed~~ the effectiveness of our internal control over financial reporting ~~based on the criteria set forth by the Committee~~as of ~~Sponsoring Organizations of the Treadway Commission ("COSO") in~~ ~~Internal Control-Integrated Framework~~. A material weakness, as defined by SEC rules, is a control deficiency, or combination of control deficiencies, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses in internal control over financial reporting that were identified are:

a) We did not maintain sufficient personnel with an appropriate level of technical accounting knowledge, experience, and training in the application of GAAP commensurate with our complexity and our financial accounting and reporting requirements. We have limited experience in the areas of financial reporting and disclosure controls and procedures. Also, we do not have an independent audit committee.December 31, 2021. As a result ~~there is~~of such review as of December 31, 2021, we identified certain deficiencies in the design and implementation of our internal controls with respect to reporting and implemented a ~~lack~~remediation plan.

Table of Contents

During half of 2022, as part of our remediation plan and procedures, we began implementing the following changes:

	·	Increasing staff resources dedicated to internal controls and reporting including the hiring of a full-time accounting assistant for the CFO who is dedicated to financial reporting;

	·	Specifically delegating roles and responsibilities for each participant in compiling and reviewing our reports including designating a single-point of contact for consolidating data inputs and delegation of key reporting elements to relevant department leads;

	·	Designating an executive team to review all narrative disclosures, including potential changes thereto. The executive team is comprised of the CEO, CFO, Director of Corporate Development, Executive Vice President of Operations, and Chief Legal Counsel;

	·	Establishing a final review process with our Chief Executive Officer and Chief Financial Officer prior to finalizing and filing our reports. At each stage of preparing financial reports the executive team conducts a review of draft materials and discusses the results in telephone conferences; and

	·	Establishing an executive review team to approve the final EDGAR version and IXBRL data file for our reports. As described above, the executive team meets and confers to review the final financial reports that are then submitted to the Audit Committee and Board for final approval prior to filing.

During the remainder of 2022, we will continue to implement our remediation plan. In connection with such plan, we expect to further increase our internal corporate resources focused on improving the design, implementation and monitoring of the financial reporting process and there is a reasonable possibility that material misstatements of the financial statements, including disclosures, will not be prevented or detected on a timely basis; and

~~b) Due to~~ our small size, we do not have a proper segregation of duties in certain areas of our financial reporting process. The areas where we have a lack of segregation of duties include cash receipts and disbursements, approval of purchases and approval of accounts payable invoices for payment. Thisinternal control ~~deficiency, which is pervasive in nature, results in a reasonable possibility that material misstatements of the financial statements will not be prevented or detected on a timely basis.~~

~~c) We do not have sufficient controls over authorization and documentation of revenue and equity transactions.~~

We will look to increase our personnel resources and technical accounting expertise within the accounting function as funds become available. Management believes that hiring additional knowledgeable personnel with technical accounting expertise will remedy the following material weakness: insufficient personnel with an appropriate level of technical accounting knowledge, experience, and training in the application of GAAP commensurate with our complexity and our financial accounting and reporting requirements.

systems.

Table of Contents

PART II - OTHER INFORMATION

ITEM 1. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. As of the date of this report, we were not aware of any ~~such~~material legal proceedings or claims ~~against us.~~

~~ITEM 2.~~

~~Unregistered Sales of Equity Securities and Use of Proceeds.~~

involving the Company.

ITEM 1A. Risk Factors.

There are no material changes to the risk factors as previously disclosed in our Form 10-K/A in response to Part I - Item 1A of our annual report filed with the SEC on April 15, 2022.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.

2021 Asset Purchase Agreement

On ~~September~~November 18, 2021, we entered into the Asset Purchase Agreement with Ainos KY, our majority shareholder. We closed the transaction on January 30, ~~2016,~~2022. Pursuant to the ~~Board~~Asset Purchase Agreement, we acquired certain intellectual property assets and certain manufacturing, testing, and office equipment for a total purchase price of ~~Directors approved~~$26,000,000. As payment of the Purchase Price, at the closing on January 30, 2022, the Company issued to ~~amend~~Ainos KY the ~~previously authorized Private Placement 2016-2 offer, sale, and issuance~~APA Convertible Note, a convertible promissory note in the principal amount of ~~unregistered securities. The Private Placement 2016-2~~$26,000,000.

On August 9, 2022, the APA Convertible Note was ~~amended to offer up to 10,000,000~~converted into 7,647,058 shares of ~~the Company's~~our common stock (on a post-split basis) at a conversion price equal to $3.40, or 80% of the per unit public offering price of ~~$.1875 per share for an aggregate~~our offering amount of $1,875,000. The offering is to be completed within one (1) year of the date of approval. On October 26, 2017, the Board of Directors unanimously approved a Consent Resolution authorizing the Company to amend the Private Placement 2016-2 offering to be extended through April 26, 2018 and to offer an additional 5,000,000 shares at a price of $.1875 per share. This amendment increased the aggregate offering amount to $2,812,500. On October 31, 2017, the Company filed the requisite Form D disclosing the amendment.

During the first quarter of 2017, the Company sold 270,000 shares of common stock at $.1875 per share for proceeds of $50,625. No shares were sold during the second quarter of 2017. During the third quarter of 2017, the Company sold 500,000 shares of common stock at $.1875 per share for proceeds of $93,750. Of the 500,000 shares soldthat closed on August 11, 2022.

2021 – 2022 Ainos KY Working Capital Advances

In 2021, Ainos KY provided working capital advances in the ~~third quarter~~form of 2017, 200,000 shares were sold to a related party, Dr. Stephen T. Chen, Chairman, CEO, and President of the Company. The shares were sold at a price per share of $.1875 for total proceeds of $37,500. Also during the third quarter, finders' feesconvertible note financing in the aggregate amount of ~~57,000 shares valued~~$3,000,000. The working capital convertible notes issued in 2021 bear interest at ~~$10,671,~~the AFR short-term rate of 1.85% and may be convertible in whole or in part at a conversion price of $0.20 per share, subject to adjustment. On March 17, 2022, we executed a Promissory Note Extension with Ainos KY dated March 17, 2022, pursuant to which the maturity dates for the convertible notes issued in 2021 to Ainos KY were extended to February 28, 2023. On August 9, 2022, notes in the aggregate principal amount of $3,000,000 plus accrued interest of $42,959 were converted by Ainos KY into a total of 1,014,319 shares of our common stock.

In March 2022, Ainos KY provided us a working capital advance in the form of a non-convertible note financing in the principal amount of $800,000, at a 1.85% per annum interest rate, with a maturity date of February 28, 2023.

Table of Contents

Convertible Note Offering Pursuant to Regulation S

The Company issued convertible notes (the “March 2027 Convertible Notes”) pursuant to Regulation S as more particularly described below:

	·	Under a Convertible Note Purchase Agreement dated as of March 31, 2022 by and between the Company and Yun-Han Liao (the “Purchaser”). The Purchaser is the daughter of Hui-Lan Wu, the Company’s Chief Financial Officer. Pursuant to the Agreement the Purchaser paid a total of $50,000 to the Company in exchange for a Convertible Promissory Note issued by the Company in the principal amount of $50,000 (the “Liao Convertible Note”).

	·	Under those certain Convertible Note Purchase Agreements dated as of March 28, 2022 (the “Regulation S Agreements”) by and between the Company and Chih-Cheng Tsai, Ming-Hsien Lee, Yu-Yuan Hsu, and Top Calibre Corporation, a British Virgin Islands company (collectively the “Regulation S Purchasers”). Pursuant to the Regulation S Agreements, the Purchasers paid a total of $850,000 (the “Principal Amount”) to the Company in exchange for Convertible Promissory Notes issued by the Company in the Principal Amount (together with the Liao Convertible Note, the “Convertible Notes”).

	·	$500,000 Convertible Note issued on April 11, 2022 to ASE Test Inc., a minority owner of Ainos KY and an affiliate of the Company.

On August 9, 2022, in connection with the listing of the Company’s common stock on the Nasdaq Capital Market, the March 2027 Convertible Notes were converted into 411,760 shares of our common stock (on a post-split basis) at a conversion price equal to $3.40, or 80% of the per unit public offering price of ~~$.1875, were paid to non-related parties~~our offering that closed on August 11, 2022.

ITEM 3. Defaults Upon Senior Securities.

None

ITEM 4. Mine Safety Disclosures.

Not applicable

ITEM 5. Other Information.

Not applicable

Table of Contents

ITEM 6. Exhibits.

EXHIBIT INDEX

			INCORPORATED BY REFERENCE
EXHIBIT NUMBER	DESCRIPTION	FILED WITH THIS FORM 10-K	FILING DATE WITH SEC	FORM	EXH #	HYPERLINK TO FILINGS

3.1	Restated Certificate of Formation of the Company, dated April 15, 2021		4/21/2021	8-K	3.1	Restated Certificate of Formation of the Company, dated April 15, 2021
3.2	Amended and Restated Bylaws of the Company, effective August 20, 2021		8/26/2021	S-1	3.2	https://www.sec.gov/Archives/edgar/data/0001014763/000165495422005505/aimd_ex32.htm
3.3	Certificate of Amendment to Restated Certificate of Formation, dated August 8, 2022		8/12/2022	8-K		https://www.sec.gov/Archives/edgar/data/1014763/000165495422011193/aimd_ex31.htm
10.1	Convertible Note Purchase Agreement dated as of April 11, 2022 between Ainos, Inc. and ASE Test, Inc.	X
10.2	Convertible Promissory Note dated April [11], 2022 issued by Ainos, Inc. to ASE Test, Inc.	X
31.1	Certification of Chief Executive Officer Pursuant to Rule 13a- 14(a) / 15d – 14(a)	X
31.2	Certification of Chief Financial Officer Pursuant to Rule 13a- 14(a) / 15d – 14(a)	X
32.1	Certification Of Principal Executive Officer Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 Of The Sarbanes-Oxley Act Of 2002	X
32.2	Certification Of Principal Financial Officer Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 Of The Sarbanes-Oxley Act Of 2002	X
99.1	Form 10-K/A for the year ended December 31, 2021		4/15/2022	10-K/A		https://www.sec.gov/ix?doc=/Archives/edgar/data/0001014763/000165495422005040/aimd_10ka.htm
100	XBRL – Related Documents	X
101.INS	XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the XBRL document.	X
101.SCH	XBRL Taxonomy Extension Schema Document	X
101.CAL	XBRL Taxonomy Extension Calculation Linkbase	X
101.DEF	XBRL Taxonomy Extension Definition Linkbase	X
101.LAB	XBRL Taxonomy Extension Label Linkbase	X
101.PRE	XBRL Taxonomy Extension Presentation Linkbase	X
104.1	Cover Page Interactive Data File	X

The exhibits listed in the Exhibit Index are filed or incorporated by reference as ~~remuneration for introducing investors to the Company. No shares~~part of this filing.

+ Schedules (as similar attachments) have been ~~sold subsequent~~omitted from this filing pursuant to ~~the balance sheet date nor through the date this report was filed.~~

Item 601(a)(5) of Regulation S-K.

* Indicates a management contract or compensatory plan or arrangement.

~~ITEM 3.~~

~~Defaults Upon Senior Securities.~~

~~None~~

~~ITEM 4.~~

~~Mine Safety Disclosures.~~26

~~Not applicable~~

~~ITEM.5.~~

~~Other Information.~~

~~None~~

~~ITEM 6.~~Table of Contents

~~Exhibits.~~

~~None~~

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	~~AMARILLO BIOSCIENCES,~~ AINOS, INC.
~~Date: November 20, 2017~~	~~By:~~ ~~/s/ Stephen T. Chen~~ ~~Stephen T. Chen, Chairman of the Board,~~ ~~and Chief Executive Officer~~
~~Date: November 20, 2017~~	~~By:~~ ~~/s/ Bernard Cohen~~ ~~Bernard Cohen, Vice President,~~ ~~Chief Financial Officer~~

Date: August 15, 2022	By:	/s/ Chun-Hsien Tsai
		Chun-Hsien Tsai, Chairman of the Board, and
		Chief Executive Officer

Date: August 15, 2022	By:	/s/ Hui-Lan Wu
		Hui-Lan Wu, Chief Financial Officer

	September 30, 2017			December 31, 2016
Assets
Current assets:
Cash and cash equivalents	$	145,029		$	134,125
Inventory		-			14,700
Advance to related party		28,584			37,835
Prepaid expense and other current assets		38,718			75,739
Total current assets		212,331			262,399
Patents, net		179,208			156,063
Property and equipment, net		31,302			44,214
Total assets	$	422,841		$	462,676

Liabilities and Stockholders' Deficit
Current liabilities:
Accounts payable and accrued expenses	$	175,339		$	165,502
Accrued interest - related parties		10,018			3,259
Advance from related party		187,500			187,500
Stock subscription deposit		142,107			-
Customer deposits – related parties		-			124,833
Convertible note payable – related party		886,481			791,481
Total current liabilities		1,401,445			1,272,575
Total liabilities		1,401,445			1,272,575

Commitments and contingencies
Stockholders' deficit
Preferred stock, $0.01 par value:
Authorized shares - 10,000,000,
Issued and outstanding shares – 0 at September 30, 2017 and December 31, 2016		-			-
Common stock, $0.01 par value:
Authorized shares - 100,000,000,
Issued and outstanding shares – 23,078,668 and 21,916,143 at September 30, 2017 and December 31, 2016, respectively		230,787			219,161
Additional paid-in capital		465,960			237,540
Accumulated deficit		(1,675,351	)		(1,266,600	)
Total stockholders' deficit		(978,604	)		(809,899	)
Total liabilities and stockholders' deficit	$	422,841		$	462,676

	Three months ended September 30						Nine months ended September 30
	2017				2016		2017				2016
Revenues:
Sales – ACM	$	-		$	-		$	250,502		$	-
Sales – Herbs		-			-			-			4.400
Total revenues		-			-			250,502			4,400
Cost of revenues:
Product sales		-			-			58,801			5,100
Total cost of revenues		-			-			58,801			5,100
Gross Margin		-			-			191,701			(700	)

Operating expenses:
Research and development expenses		-			-			-			-
Selling, general and administrative expenses		230,875			178,470			592,822			434,176
Total operating expenses		230,875			178,470			592,822			434,176

Operating loss		(230,875	)		(178,470	)		(401,121	)		(434,876	)

Other income (expense):
Interest expense		(1,929	)		(798	)		(7,630	)		(2,257	)
Net loss		(232,804	)	$	(179,268	)		(408,751	)	$	(437,133	)

Basic and diluted net loss per share	$	(0.01	)	$	(0.01	)	$	(0.02	)	$	(0.02	)

Weighted average shares outstanding – basic and diluted		22,789,370			21,394,810			22,500,663			20,871,635


	Nine months ended September 30, 2017			Nine months ended September 30, 2016

Net cash used in operating activities:	$	(188,526	)	$	(426,988	)

Cash flows from investing activities:
Investment in equipment		-			(47,685	)
Investment in patents		(39,945	)		(54,483	)
Net cash used in investing activities		(39,945	)		(102,168	)

Cash flows from financing activities:
Proceeds from private placement offering		144,375			421,875
Proceeds from convertible note payable – related party		95,000			262,500
Net cash provided by financing activities		239,375			684,375

Net change in cash		10,904			155,219
Cash and cash equivalents at beginning of period		134,125			21,138
Cash and cash equivalents at end of period	$	145,029		$	176,357
Supplemental disclosure of cash flow information
Cash paid for interest	$	-		$	1,066
Cash paid for income taxes	$	-		$	-
Noncash transactions:
Common stock shares issued for services	$	10,671		$	-
Conversion of accounts payable – related party to convertible note payable – related party	$	-		$	144,426
Conversion of notes payable – related party to convertible note payable – related party	$	-		$	384,555

	September 30, 2017		December 31, 2016
Convertible Note payable – related party	$	144,426	$	144,426
Convertible Note payable – related party		262,500		262,500
Convertible Note payable – related party		384,555		384,555
Convertible Note payable – related party		70,000		-
Convertible Note payable – related party		25,000		-
Convertible Notes payable – related party	$	886,481	$	791,481